Introduction {#Sec1}
============

Nanotechnology may have important applications in multiple biomedical fields (Williams et al. [@CR27]; Heller et al. [@CR13]; Elder et al. [@CR6]; Jain [@CR14]; Cai et al. [@CR4]; Fenske and Cullis [@CR9]; Bianco et al. [@CR2]; Martin and Kohli [@CR19]; Liu et al. [@CR17]; Ni et al. [@CR21]; Sun et al. [@CR24]; Zanello et al. [@CR29]; Bianco et al. [@CR3]; Hartman et al. [@CR12]), and the use of nanomaterial in cancer treatment is particularly intriguing (Fifis et al. [@CR10]; Farokhzad et al. [@CR8]). One important issue in cancer immunology is the search of novel immune adjuvants that can enhance the efficacy of anti-tumor immunotherapy (Mesa and Fernandez [@CR20]). Immunotherapy is an important form of adjunctive cancer treatment that may significantly improve the prognosis (Vermorken et al. [@CR26]; Schirrmacher [@CR23]; Takayama et al. [@CR25]). Prior clinical trials of immunotherapy have achieved promising results in treating malignancies such as melanoma, malignant glioma, or renal cell carcinoma (Berd et al. [@CR1]; Yu et al. [@CR28]; Rosenberg et al. [@CR22]), which tend to respond poorly to chemotherapies. Nevertheless, the efficacy of current anticancer immunotherapy generally needs further improvement (Emens [@CR7]). Because tumor antigens are usually self-derived and are, therefore, poorly immunogenic, the adjuvants for anticancer immunotherapy have to be more potent than for prophylactic vaccines (Mesa and Fernandez [@CR20]). One way to increase the efficacy is using immune adjuvants, which are defined as products that increase the immune response toward antigens. The identification of novel and more efficacious adjuvants is thus of practical importance for anticancer immunotherapy (Mesa and Fernandez [@CR20]; Emens [@CR7]).

Aluminum nanoparticle (nano-alum) may serve as a candidate of prospective adjuvant for anticancer immunotherapy, which needs to be both safe and efficacious. Alum (aluminum hydroxide, phosphate, or hydroxyphosphate) has an excellent safety record for systemic vaccination. It has been used as adjuvant for more than 60 years and is at present the most widely used adjuvant in both veterinary and human vaccines (Mesa and Fernandez [@CR20]; Lindblad [@CR16]). However, alum is mostly a Th2 stimulator of the immune system and primarily enhances the antibody-mediated reaction (Lindblad [@CR16]). It has limited influence on the cytotoxic T cell-mediated response, which is considered the main mechanism of anticancer immune effects (Mesa and Fernandez [@CR20]; Berd et al. [@CR1]; Lindblad [@CR16]). Since nanosized materials often exhibit unique properties that may offer significant advantage for biomedical applications (Jain [@CR14]; Martin and Kohli [@CR19]), it is sensible to investigate if nano-alum will be more efficacious in enhancing anticancer immune response than conventional alum. Here, we studied whether nano-alum would influence the efficacy of an immunotherapy that employs tumor cell vaccine (TCV), to evaluate nano-alum's applicability as an adjuvant in a commonly used anticancer immune regimen.

Materials and methods {#Sec2}
=====================

Compounds {#Sec3}
---------

Nano-alum (Al~2~O~3~, MW 101.96) was purchased from Degussa Nanotechnology of Evonik Industries. Scanning electron microscopy (SEM) was performed to evaluate the size of the nanoparticles. Conventional alum in the form of Al(OH)~3~ (analytical grade, MW 78.0) was purchased from Beijing Chemical Reagents Company.

Animal {#Sec4}
------

BALB/c mice were purchased from the Experimental Animal Institute of the Chinese Academy of Medical Sciences (Beijing, China), bred and maintained under defined flora conditions in individually ventilated (high-efficiency particle-arresting filtered air) sterile microisolator cages (Techniplast, Milan, Italy). All animal handling and experimental procedures were approved by the Animal Care and Use Committee of the Chinese Academy of Medical Sciences.

Preparations of alum or nano-alum adjuvants {#Sec5}
-------------------------------------------

Conventional alum in the form of Al(OH)~3~ was mixed with D-Hanks solution at a concentration of 500 µg per ml (6.4 mM/l) and fully sonicated, yielding a suspension ready for further use. Nano-alum was mixed with D-Hanks solution at the concentration of 326.9 µg per ml, to ensure that the final molar concentration of nano-alum (6.4 mM/l) is the same as that of the conventional alum adjuvant. The nano-alum mixture was then sonicated immediately prior to application, yielding a semi-clear solution ready for immune studies.

Preparations of tumor cell vaccine {#Sec6}
----------------------------------

TCV was prepared by incubating H22 liver cancer cells in D-Hanks solutioin containing Mitomycin C (80 mg/l) for 60 min, followed by thorough wash with D-Hanks for five times.

Experiments of immunotherapy {#Sec7}
----------------------------

Immunotherapy experiments were conducted using female adult BALB/c mice, 8 weeks of age, weighing 18 to 22 g. Twenty-eight mice were randomly divided into four groups: (1) the control group, (2) the TCV treatment group, (3) the TCV plus conventional alum (TCV + alum) treatment group, and (4) the TCV plus nano-alum (TCV + nano-alum) treatment group. On day zero, every mouse was inoculated with 2 × 10^6^ live H22 cells subcutaneously in the right hind leg. On day 7 and 14, the treatment groups also received two subcutaneous doses of designed immune treatment agents in the left hind leg for triggering anti-tumor reactions. Specifically, the TCV group received 2 × 10^6^ TCV cells in 200 µl D-Hanks; the TCV + alum group received 2 × 10^6^ TCV cells in 100 µl D-Hanks mixed with 100 µl of alum adjuvant; and the TCV + nano-alum group received 2 × 10^6^ TCV cells in 100 µl D-Hanks mixed with 100 µl of nano-alum adjuvant. On day 7 and day 14, the control group also received injections of 200 µl D-Hanks that did not contain TCV or adjuvant. Tumor dimensions were monitored using calipers at right angles every 3 to 4 days. The tumor size was measured using the product of the two longest dimensions perpendicular to each other.

Immune cytotoxicity studies {#Sec8}
---------------------------

Animals randomly picked from all groups were terminated on day 30, and peripheral blood lymphocytes were extracted and co-incubated with the H22 tumor cells. Ten thousand H22 tumor cells (target cells) were seeded on the bottom of 96-well plates (Falcon) at a density of 2 × 108/L. Periphery murine blood monocytes/lymphocytes (effector cells) were obtained through standard Ficoll gradient centrifugation. Effector cells (1 × 10^5^ in 50 μL) were added to the target cells, keeping the effector-to-target ratio at 10:1. The final combined volume per well was 100 μL. Tissue culture plate was centrifuged at 250 rpm for 5 min to ensure cell--cell contact, then incubated at 37°C with 5% CO~2~ for 4 h. The lactate dehydrogenase (LDH) assay reagents were added per manufacturer's (Promega) instruction. The optical density of the supernatant was measured using an ELISA plate reader with a 490 nm filter. The values of effector cells' spontaneous LDH release, target cells' spontaneous LDH release, target cells' maximum LDH release, and culture medium background reading were also measured. The percentage of target cell killed was then calculated per manufacturer's protocol. The percent tumor cell killed was calculated according to the following equation: $$\documentclass[12pt]{minimal}
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Histological studies of the tumor tissue {#Sec9}
----------------------------------------

Tumor tissues were fixed and imbedded in paraffin. Tumor sections of 5 μm were cut from the embedded tissue and stained by standard hematoxylin and eosin procedure (HE stain), for evaluation of tumor necrosis and lymphocyte infiltration.

Statistics {#Sec10}
----------

Statistical analysis was performed with the statistical SPSS 13.0 software. The nonparametric test was used to calculate the probability of significant differences among the groups. Statistical significance was defined as *p* \< 0.05.

Results {#Sec11}
=======

Characterization of the nano-alum {#Sec12}
---------------------------------

SEM of the nano-alum was carried out to evaluate the size of the nanoparticles. The average diameter of the aluminum nanoparticles was 20--30 nm (Fig. [1a and b](#Fig1){ref-type="fig"}). For immune experiments, nano-alum adjuvant was freshly made through mixing with D-Hanks solution, and sonicated immediately prior to the injection, yielding semi-clear solution that was stable and without precipitation for the entire duration of the experiment. Fig. 1Scanning electron microscopy images of the aluminum nanoparticle at low (**a**) and high resolutions (**b**). The average particle size was about 20--30 nm

Tumor size study {#Sec13}
----------------

The animal study employed the H22 murine hepatoma because it was a mature tumor model that had been frequently used in immunotherapy research (Luo et al. [@CR18]). The outcome of the immune treatment was assayed directly by the tumor size. The individual tumor growth curve of each animal was provided in Fig. [2a](#Fig2){ref-type="fig"}. After inoculation with H22 cells, most animals gradually developed detectable subcutaneous tumor mass in 5 to 10 days. In the control group, most tumors steadily increased in size over the entire duration of the experiment, whereas in the treatment groups, some tumors tended to grow at slower rate. Moreover, in some animals that received treatments, the tumors stopped growing and gradually shrank in size after about 20 days (Fig. [2a](#Fig2){ref-type="fig"}). The averaged tumor size of each group was shown in Fig. [2b](#Fig2){ref-type="fig"}: all the treatment groups tended to have lower average tumor size than the control group, with the lowest average tumor size belonging to the TCV + nano-alum group. On day 14, the tumor size of the control group, the TCV group, the TCV + alum group, and the TCV + nano-alum group was 31.71 ± 8.53 mm^2^, 15 ± 2.88 mm^2^, 7.71 ± 1.83 mm^2^, and 6.42 ± 2.22 mm^2^, respectively. On this day, both the TCV + alum and the TCV + nano-alum groups had significantly smaller average tumor size compared to the control group (*p* \< 0.05). From day 18 to day 30, the differences in average tumor size among the groups gradually became more prominent. On day 30, the tumor size was 91 ± 22.69 mm^2^ for the control group, 61.27 ± 27.63 mm^2^ for the TCV group, 72.28 ± 26.05 mm^2^ for the TCV + alum group, and 40.85 ± 17.18 m^2^ for the TCV + nano-alum group. The difference between the TCV + nano-alum group and the control group was statistically significant (*p* \< 0.05) on days 18, 22, 26, and 30, whereas none of the other treatment groups showed a significant difference from the control group. The results suggested that nano-alum probably enhanced the anticancer reaction more efficiently, resulting in the lower average tumor size observed in the TCV + nano-alum group. Fig. 2Tumor growth studies with the tumor size measured every 4 days. **a** Individual tumor growth curves of each experiment group. **b** Average tumor size of each experiment group (±SE, *n* = 7 for each group). The *star* indicates a statistically significant difference (*p* \< 0.05) from the control group

Immune cytotoxicity studies {#Sec14}
---------------------------

To explore the mechanism of the improved outcome observed in the treatment groups, cellular immunological experiments were conducted. Specifically, the lymphocytes' anti-tumor cytotoxicity was evaluated and compared among the groups. Animals randomly picked from all groups were terminated on day 30, and peripheral blood lymphocytes were extracted and co-incubated with the H22 tumor cells. The cytotoxic effects of the lymphocytes against the H22 cells were then measured using a standard LDH assay. As shown in Fig. [3](#Fig3){ref-type="fig"}: the percentage of tumor cell killed was 9.9 ± 6.9 for the control group, 30.1 ± 3.09 for the TCV group, 35.63 ± 2.8 for the TCV + alum group, and 67.96 ± 9.54 for the TCV + nano-alum group. Thus, the TCV + nano-alum group generated significantly higher anticancer cytotoxicity compared to the other treatment groups (*p* \< 0.05). The results suggested that nano-alum had a more potent adjuvant effect than conventional alum, and better enhanced the anti-tumor response induced by TCV. Fig. 3In vitro anti-tumor cytotoxicity studies. The lymphocytes' cytotoxicity against the H22 tumor cells were measured using a standard LDH assay at day 30 of the experiment. The most potent anti-tumor cytotoxicity was observed in the TCV + nano-alum group (\**p* \< 0.05, ±SE, *n* = 6)

Histological studies of the tumor tissue {#Sec15}
----------------------------------------

Histological studies of the tumor tissue were also performed to evaluate the treatment outcome. The tumor tissue of the control group was found relatively well maintained with minimal lymphocyte infiltration (Fig. [4a](#Fig4){ref-type="fig"}). In the treatment groups, however, the tumor tissues were infiltrated with more lymphocytes (Fig. [4b, c, d](#Fig4){ref-type="fig"}). Moreover, the tumor tissue of the TCV + nano-alum group developed obvious necrosis (Fig. [4d](#Fig4){ref-type="fig"}), suggesting that anti-tumor immune reaction was actively in process. Fig. 4Histological slides of the tumor tissues stained with hematoxylin and eosin. **a** Control group. **b** TCV group. **c** TCV + alum group. **d** TCV + nano-alum group. Lymphocyte infiltrations were found in all the treatment groups (**b**, **c**, **d**, *arrowheads*). Tumor necrosis was observed in the TCV + nano-alum group (**d**, *straight arrow*)

Discussion {#Sec16}
==========

The aim of this study was to investigate if nano-alum would be a more potent adjuvant than conventional alum in an anti-tumor immunotherapy employing TCV. The result showed that nano-alum enhanced lymphocytes' cytotoxicity against the H22 liver cancer cells, whereas conventional alum failed to generate a positive immune stimulating effect (Fig. [3](#Fig3){ref-type="fig"}). The average tumor size in the TCV + nano-alum group also tended to be lower (Fig. [2](#Fig2){ref-type="fig"}), presumably because of the enhanced anti-tumor immune cytotoxicity in this group. In addition, histological study also revealed increased lymphocyte infiltration and tumor necrosis in the TCV + nano-alum group (Fig. [4](#Fig4){ref-type="fig"}), again suggesting that nano-alum boosted the anti-tumor response.

Frey et al. reported that aluminum nanoparticles chemically conjugated to the C4 domain of the gp120 HIV protein can generate relatively high antibody response toward gp120 (Frey et al. [@CR11]). Here, we showed that nano-alum alone, without conjugation to antigen, could enhance the TCV-induced anticancer immune response, and that conventional alum failed to generate a similar effect (Fig. [3](#Fig3){ref-type="fig"}). Both studies suggest that nano-alum is a more potent immune adjuvant than conventional alum. This presumably could be attributed to the unique physical and chemical properties of nano-alum, which might be more favorable for immune stimulation. It should be noted, however, that the detailed mechanisms of both conventional alum and nano-alum adjuvants remain to be unveiled to date (Lindblad [@CR16]), and much further research is still warranted.

TCV was used in this study for triggering immune response. TCV carries a mixture of tumor proteins and is multivalent in terms of tumor antigens (Copier and Dalgleish [@CR5]). The major advantage of TCV is that it may be applied in treatment of multiple malignancies, irrespective of the genetic makeup of the cancer. However, the lack of clearly defined tumor antigens in TCV therapy renders the antibody responses difficult to assess. Because the nature of the immunogens was not known, the efficacy of TCV therapy was generally measured by tumor growth retardation or prolonged survival, and not by antibody production (Copier and Dalgleish [@CR5]; Levy and Colombetti [@CR15]). Nevertheless, some clinical studies based on such vaccines have generated promising results (Vermorken et al. [@CR26]; Schirrmacher [@CR23]). In this study, nano-alum was found to enhance the anti-tumor immunity induced by TCV. Since TCV can often be made from surgically resected tumors, nano-alum thus may have potential application in immune treatment of multiple types of tumors that are surgically accessible.

In summary, this study showed that nano-alum enhanced the anticancer immune response induced by TCV. The results suggest that nano-alum may potentially serve as an effective adjuvant in anticancer immunotherapies.
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